Zacks: OpGen, Inc. (OPGN) Given Average Rating of “Strong Buy” by Analysts
OpGen, Inc. (NASDAQ:OPGN) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $1.50 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 176 out of 265 based on the ratings given to its competitors.
A number of research firms recently issued reports on OPGN. Zacks Investment Research raised shares of OpGen from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research note on Tuesday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $1.00 price target on shares of OpGen in a research note on Tuesday, October 24th.
An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned about 2.72% of OpGen as of its most recent SEC filing. 12.21% of the stock is owned by hedge funds and other institutional investors.
Shares of OpGen (NASDAQ:OPGN) opened at $0.26 on Thursday. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03. OpGen has a 12 month low of $0.20 and a 12 month high of $3.10.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.